Financial News
All News about Royalty Pharma Plc Cl A
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Royalty Pharma
May 08, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://mms.businesswire.com/media/20230823459614/en/296364/5/Ferring_RGB_Logo_JPG.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Reports Second Quarter 2023 Results
August 08, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://g.foolcdn.com/editorial/images/740650/a-person-smiling-and-reviewing-their-finances.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Declares Third Quarter 2023 Dividend
July 17, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](/next-assets/images/schema-image-default.png)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_11492.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_11445.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://www.investors.com/wp-content/uploads/2023/06/A1-060523-Bigpharma-chrisgash.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_10085.jpeg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
![](https://cdn.benzinga.com/files/images/story/2023/05/09/rprx.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://mms.businesswire.com/media/20230323005234/en/1396139/5/2022_Horizontal_transparent_white.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Raises Full Year 2023 Guidance
March 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.